Optimi Health (TSE:OPTI) has released an update.
Optimi Health Corp., a Canadian psychedelics manufacturer, has announced a partnership with PsiloThai to conduct research on psilocybin in Thailand, targeting addiction and end-of-life distress treatments. This collaboration, following Thailand’s regulatory changes on psilocybin, represents Optimi’s first step into the Asian medical market. The joint research will utilize Optimi’s GMP natural psilocybin extract capsules and is pending formal approval by Thai health authorities.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
